CAS 1562993-37-6

Formel: C29H27F3N6O

InChl: InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)/i12D2,13D2,14D2,15D2

InChI Key: PHXJVRSECIGDHY-DHNBGMNGSA-N

SMILES: [2H]C1(C(N(C(C(N1C)([2H])[2H])([2H])[2H])CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)C#CC4=CN=C5N4N=CC=C5)C(F)(F)F)([2H])[2H])[2H]

Ponatinib-d8

CAS: 1562993-37-6

Reinheit: 99.91%

Ref: IN-DA01LJ0Y

Ponatinib-d8

CAS: 1562993-37-6

Ponatinib-d8

Formel: C₂₉H₁₉D₈F₃N₆O

Reinheit: 99.91%

Molekulargewicht: 540.61

Ref: 54-DE2301

Ponatinib-d8

CAS: 1562993-37-6

Formel: C₂₉H₁₉D₈F₃N₆O

Farbe und Form: Pale Yellow Solid

Molekulargewicht: 540.62

Ref: 4Z-P-123002

Ponatinib-D8

CAS: 1562993-37-6

Ponatinib D8 is a deuterium-enriched, oral multi-kinase inhibitor (Abl, PDGFRα, VEGFR2, FGFR1, Src; IC50s: 0.37-5.4 nM).

Formel: C₂₉H₂₇F₃N₆O

Reinheit: 98%

Farbe und Form: Solid

Molekulargewicht: 540.61

Ref: TM-T12521

Ponatinib-d8

Kontrolliertes Produkt

CAS: 1562993-37-6

Applications Ponatinib-d8 is an isotope labelled compound of Ponatinib (P688250). Ponatinib is a tyrosine kinase inhibitors (TKI) and used to treat chronic myeloid leukemia (CML) (1,2,3). Ponatinib is also used in combination with other drugs, such as forskolin, to combat TKI resistance in patient with CML (3), targeted drug in small-cell lung cancer. It is a COVID19-related research product.
References Skora, L., et al.: ACS Med. Chem. Lett., PagesAhead of Print (2017); Uchibori, K., et al.: Nat. Commun., 8, 14768 (2017); Perrotti, D., et al.: Curr. Drug Targets, 18, 377 (2017); Santarpia, M., et al.: Trans. Lung Cancer Res., 5, 51 (2016); Halbach, S., et al.: Cell Commun. Signal., 14, 6 (2016)

Formel: C₂₉H₁₉D₈F₃N₆O

Farbe und Form: Neat

Molekulargewicht: 540.61

Ref: TR-P688252

Ponatinib-[d8]

CAS: 1562993-37-6

Ref: BE-MD-7100

Ponatinib-d8

CAS: 1562993-37-6

Ref: BE-RMCP284001